Skip to content

Compareing effects of kinds of drugs on menopausal symptoms

Compareing effects of Calci Soya Balance and Vitagnuse on menopausal symptoms in Tehran

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201102215878N1
Enrollment
70
Registered
2011-08-11
Start date
2011-09-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menopausal symptoms. Other obstetric conditions, not elsewhere classified

Interventions

Intervention 1: First group will be given Tab Vitagnus oral, 2 times daily for 8 weeks. Intervention 2: Second group will be given Tab Calci Soya Balance oral, 1 time daily for 8 weeks.
Treatment - Drugs
First group will be given Tab Vitagnus oral, 2 times daily for 8 weeks.
Second group will be given Tab Calci Soya Balance oral, 1 time daily for 8 weeks.

Sponsors

Research deputy of Tehran University of Medical sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Inclusion criteria:menopause women with at least one year after amenorrhea history; that suffer of menopausal symptoms. Exclusion criteria:have history of Brest cancer; take Tamokcifen;take chemotropic;have malignancy; have active hepatic or renal disease; take HRT or other menopausal treatments; take progesterone or androgen.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Menopausal symptoms. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Kupperman menopausal index.

Secondary

MeasureTime frame
Itch, nausea, diarrhea. Timepoint: End of every week by calling. Method of measurement: by answering to our questions in phone.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Bazzazian

Nursing and Midwifery Faculty of Tehran University of Medical sciences

shbazzazian@yahoo.com+98 21 6692 7171

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026